文献速递其他结缔组织病

核酸酶治疗改善原发性干燥综合征患者严重疲劳:一项随机临床试验

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial.
PubMed 文献 · Arthritis Rheumatol · 2020-11-22

这项II期随机双盲安慰剂对照试验评估了RSLV-132(一种RNase Fc融合蛋白)在原发性干燥综合征患者中的安全性和有效性。结果显示,接受RSLV-132治疗的患者在ESSPRI、FACIT-F、ProF和DSST等疲劳相关指标上从基线至第99天出现临床有意义的改善,而安慰剂组无变化;改善与干扰素诱导基因表达增加显著相关。

要点

  • RSLV-132治疗使原发性干燥综合征患者疲劳指标出现临床有意义的改善。
  • 安慰剂组在所有临床疗效指标上均无变化。
  • 疲劳改善与干扰素诱导基因表达增加显著相关。

核心结论

  • RSLV-132可改善原发性干燥综合征患者的严重疲劳,该结论基于4项独立的患者报告疲劳指标。

研究设计与样本

  • 给药方案为每周1次连续2周,之后每2周1次持续12周;8例接受安慰剂,20例接受RSLV-132 10 mg/kg。

主要发现

  • RSLV-132组从基线至第99天ESSPRI评分改善P=0.27,FACIT-F评分改善P=0.05,ProF评分改善P=0.07,DSST改善P=0.02。
  • 安慰剂组在所有临床疗效指标上均无变化。
  • 疲劳改善与特定干扰素诱导基因表达增加显著相关(Pearson相关,每个P<0.05)。

关键数值与推荐

  • 临床疗效指标包括EULAR干燥综合征疾病活动指数、EULAR干燥综合征患者报告指数(ESSPRI)、慢性病治疗功能评估-疲劳量表(FACIT-F)、疲劳概况(ProF)和数字符号替换测试(DSST)。

临床怎么用

  • 对于原发性干燥综合征的严重疲劳,RSLV-132可能是一种有前景的治疗选择,但需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the safety and efficacy of RSLV-132, an RNase Fc fusion protein, in a phase II randomized, double-blind, placebo-controlled clinical trial in patients with primary Sjögren's syndrome (SS). METHODS: Thirty patients with primary SS were randomized to receive treatment with RSLV-132 or placebo intravenously once per week for 2 weeks, and then every 2 weeks for 12 weeks. Eight patients received placebo and 20 patients received RSLV-132 at a dose of 10 mg/kg. Clinical efficacy measures included the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Profile of Fatigue (ProF), and the Digit Symbol Substitution Test (DSST). RESULTS: Patients randomized to receive RSLV-132 experienced clinically meaningful improvements in the ESSPRI score (P = 0.27), FACIT-F score (P = 0.05), ProF score (P = 0.07), and DSST (P = 0.02) from baseline to day 99, whereas patients who received placebo showed no changes in any of these clinical efficacy measures. This improvement was significantly correlated with increased expression of selected interferon-inducible genes (Pearson's correlations, each P < 0.05). CONCLUSION: Administration of RSLV-132 improved severe fatigue, as determined by 4 independent patient-reported measures of fatigue, in patients with primary SS.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Posada J, Valadkhan S, Burge D, et al. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial. Arthritis Rheumatol. 2020. PMID: 32798283. doi:10.1002/art.41489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。